Karmacharya @rheum_cat et al. Comorbidity clusters in AS. Depression cluster associated higher disease activity and worse function over time. @RheumNow #ACR22 Abstr#1609 https://t.co/lFVoyhy5UQ https://t.co/26EjzXULGr

• Comorbidity Clusters in Ankylosing Spondylitis and Their Association with Disea…

The pandemic has brought many challenges to our community. One of them is the lingering effects of COVID-19. #PASC #COVID #ACR22 #RheumTwitter https://t.co/AlwUHX2cao

• Long COVID and Rheumatic Disease | RheumNow

Spinal lesions on MRI in axSpA is ~3% in patients with negative imaging in SIJ on MRI or X-ray. Agreement in >5/9 central readers. Frequency of spinal vertebral corner BME lesions was significantly higher these cases. Maksymovych Abs#2257 https://t.co/56yxGxBgLp #ACR22 @RheumNow https://t.co/CkJ9o2dJuT

• MRI Spinal Lesions in Patients Without MRI or Radiographic Lesions in the Sacro…

Mease et al. TYK2i Deucravacitinib in PsA. Phase 2 RCT 52 week results. PASDAS, DAPSA efficacy maintained through week 52. No new safety concerns. @RheumNow #ACR22 Abstr#1598 https://t.co/sRKkgkYtQJ https://t.co/YMXMEH3wsq

• Safety and Efficacy of Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 In…

Ogdie @AlexisOgdie et al. CorEvitas, PsA treatment after 1st line TNFi failure. Switching MOA probably more effective @RheumNow #ACR22 Abstr#1600 https://t.co/vy8gxDaYxZ https://t.co/NmkESbSNfL

• The Impact of Second-Line Therapeutic on Disease Control After Discontinuation …

#ACR22 Abstr#1764 In addition to race, what social health aspect to consider when assessing #lupus epidemiology? A study identified urbanicity and area deprivation index were associated with SLE diagnosis. Could those living in the city = better access and diagnosis? @RheumNow https://t.co/PsNt8vQufs

#ACR22 Abstr#2033 How negative is sero-ve #Sjogren? A study discovered new autoantibodies using Peptidome Array Technology. AUC for these 8 peptides was excellent 0.97. Mainly in White/Hispanic. Need validation in other groups and association with other markers/biopsy @RheumNow https://t.co/xAFrjK9mS3

Urine Proteomics in SLE with Dr. Michelle Petri Dr. Michelle Petri discusses abstract 0536, Change in Urinary Biomarkers at Three Months Predicts 1-year Treatment Response of Lupus Nephritis Better Than Proteinuria, being presented Saturday at #ACR22. https://t.co/rBDnbSqQCI https://t.co/WfERf1k5VB

• https://bit.ly/3UUdey4

Clinical Year in Review | Presented by Dr. Carol Langford at #ACR22 🌟 Review the Most Important Clinical Research Studies in the Past Year in #Rheumatology! 💫 https://t.co/Ao11xX1bYt

Preventing #rheumatoid #arthritis - the holy grail! STOPRA RCT of strong ACPA+; CCP3 high titre. No inflammatory arthritis. RCT of #Hydroxychloroquine vs placebo, N=142 Pts. At 3 yrs NO DIFF in onset@of RA in each group. identical curves. Abst1604 #ACR22 #ACRBest @RheumNow Darn! https://t.co/bEgbkxGSR4

#ACRBest Abstracts - Day 2 Day two at #ACR22 was full of great sessions on imaging, vasculitis, lupus, vasculitis, spondyloarthritis, COVID, pregnancy, microbiome, economics and more. Here are the RheumNow faculty selections for today. https://t.co/lAG1v2dHKQ https://t.co/oAG6zE7QzX

• https://bit.ly/3WY4yIO

Pike M Abstract 1113. Remibrutinib (LOU064) in Sjögren’s Syndrome: Safety and Efficacy Results from a 24‑Week Placebo-controlled Proof-of-Concept Study #ACRBest #ACR22 @RheumNow